The effects of RASi administration on the rates of cardiovascular disease and heart failure and on the rates of death have also been reported [4-6,18-20,21 ]. In the Dialysis Outcomes Practice Pattern Study in Japan (J-DOPPS), RASi had no beneficial effects on cardiovascular events [22]. This evidence concerns the gene MMP19 and heart failure.